At Myllia, pooled CRISPR screens are performed at large scale, and our unique platform involves a broad portfolio of CRISPR/Cas9 technologies
Cell-based CRISPR screens have become a primary engine in modern drug target discovery. We employ customized CRISPR screens in many different cellular models including T cells and CRISPR-engineered cancer cells. On top, we can customize CRISPR screens specifically to your needs including functional assay development.
Submit your credentials and explore our capabilities and functional read-outs!